Trial Profile
A retrospective study evaluating the impact of replacing PCV7 with PCV13 on disease burden in adults, and identified age/risk-specific subgroups with highest remaining disease burden
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Oct 2018
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Oct 2018 New trial record
- 20 Sep 2018 Results published in the Clinical Infectious Diseases